Dolutegravir-based Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 (HIV-2) Infection: Progress for People With HIV-2
- PMID: 37288974
- DOI: 10.1093/cid/ciad340
Dolutegravir-based Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 (HIV-2) Infection: Progress for People With HIV-2
Conflict of interest statement
Potential conflicts of interest. G. S. G. has received research grants or contracts from the National Institutes of Health (NIH), University of Washington, Bill & Melinda Gates Foundation; Gilead Sciences, Inc.; Alere Technologies; and Cerus Corporation; non-financial support via human immunodeficiency virus drugs or testing equipment from Janssen Pharmaceuticals; Merck & Co., Inc.; Gilead; ViiV Healthcare; Bristol-Myers Squibb; Roche Molecular Systems; Abbott Molecular Diagnostics; and THERA Technologies/TaiMed Biologics, Inc. G. S. G. also reports royalties from UpToDate.
Comment on
-
Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study.Clin Infect Dis. 2023 Sep 11;77(5):740-748. doi: 10.1093/cid/ciad339. Clin Infect Dis. 2023. PMID: 37288954 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical